A Randomized, Open-label, Single-dose, Crossover Study to Evaluate the Pharmacokinetics and Safety/Tolerability of BR4002 Comparing to BR4002-1 in Healthy Volunteers
Latest Information Update: 30 Oct 2020
At a glance
- Drugs BR-4002 (Primary) ; BR-4002 (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Boryung Pharmaceutical
- 27 Oct 2020 Status changed from recruiting to completed.
- 10 Jul 2020 New trial record